|
Current issue
Archive
Videos
Articles in press
About the journal
Supplements
Editorial board
Reviewers
Abstracting and indexing
Subscription
Contact
Instructions for authors
Ethical standards and procedures
Editorial System
Submit your Manuscript
|
4/2007
vol. 109 abstract:
Original paper
The results of wet AMD treatment by intravitreal injections – preliminary report
Anna Okruszko
1
,
Anna I. Borucka
1, 2
,
Magdalena Ulińska
1, 2
,
Jerzy Szaflik
1
Klinika Oczna 2007, 109 (4): 389-393
Online publish date: 2007/12/20
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Age-related macular degeneration (AMD) is the leading cause of irreversible, severe loss of vision in the developed countries.
Age-related macular degeneration (AMD) is the leading cause of irreversible, severe loss of vision in the developed countries. One of the modern methods of treatment in neovascular form of AMD are repeated intravitreal injections of ranibizumab (Lucentis®). Ranibizumab is a recombinant, humanized, monoclonal antibody that neutralizes all biologically active forms of vascular endothelial growth factor A (VEGF-A). The aim of the study was to analyze the results of intravitreal ranibizumab injections in wet AMD patients. There were 57 patients enrolled in the study. 87% of them avoided any loss of visual acuity and 47.3% gained at least one line at visual acuity chart. Authors conclude that treatment with repeated intravitreal injections of ranibizumab is effective in neovascular form of AMD. keywords:
age-related macular degeneration, AMD, choroidal neovascularization, ranibizumab, intravitreal injection |
|
POLSKI
